Effects of growth hormone on pregnancy rates of patients with thin endometrium
To investigate whether growth hormone (GH) could improve pregnancy rates of patients with thin endometrium by clinical study and laboratory experiments.
Materials and methods
Ninety-three patients were randomized to either the GH-received group (40) or the routine exogenous administration of estrogens control group (53) for clinical study. The human endometrial carcinoma cell line RL95-2 was used for testing the role of GH with Western blot and real-time PCR by exposure to various concentrations of GH (0.1 nM,1 nM,10 nM,100 nM).
Patients treated with GH had a significantly (P < 0.05) greater endometrium thickness on day 3 (7.87±0.72 vs 6.34±0.86), higher implantation rates (24.4% vs 10.5%) and greater clinical pregnancy rates (42.5% vs 18.9%) compared with the control group. No adverse events were associated with the use of GH. Administration of GH significantly up-regulated the expression of VEGF, ItgB3 and IGF-I expression in RL95-2 cells at both mRNA and protein levels (P < 0.05). AG490, an inhibitor of JAK2, nearly completely inhibited the up-regulative effect of GH through the JAK2-STAT5 pathway, and GH-induced effects could be mediated through autocrine IGF-I together with its hepatic counterpart. IGF-I mRNA was detected in the RL95-2 cells.
GH may improve pregnancy outcomes of patients with thin endometrium who undergo frozen embryo transfer by acting on human endometrial cells to promote proliferation and vascularization and to up-regulate receptivity-related molecular expression.
KeywordsEndometrial thickness Growth hormone Pregnancy rate Cell experiment Mechanism
This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.
Compliance with ethical standards
Conflict of interest
We declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 12.Oliveira CR, Salvatori R, Nobrega LM, Carvalho EO, Menezes M, Farias CT, Britto AV, Pereira RM, Aguiar-Oliveira MH (2008) Sizes of abdominal organs in adults with severe short stature due to severe, untreated, congenital GH deficiency caused by a homozygous mutation in the GHRH receptor gene. Clin Endocrinol (Oxf) 69:153–158CrossRefGoogle Scholar
- 13.Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, Wei M, Madia F, Cheng CW, Hwang D, Martin-Montalvo A, Saavedra J, Ingles S, de Cabo R, Cohen P, Longo VD (2011) Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med 3:70ra13CrossRefGoogle Scholar
- 19.Li XL, Wang L, Lv F, Huang XM, Wang LP, Pan Y, Zhang XM (2017) The influence of different growth hormone addition protocols to poor ovarian responders on clinical outcomes in controlled ovary stimulation cycles: a systematic review and meta-analysis. Medicine (Baltimore) 96:e6443CrossRefGoogle Scholar
- 22.Rajesh H, Yong YY, Zhu M, Chia D, Yu SL (2007) Growth hormone deficiency and supplementation at in vitro fertilisation. Singap Med J 48:514–518Google Scholar
- 23.Conway-Campbell BL, Wooh JW, Brooks AJ, Gordon D, Brown RJ, Lichanska AM, Chin HS, Barton CL, Boyle GM, Parsons PG, Jans DA, Waters MJ (2007) Nuclear targeting of the growth hormone receptor results in dysregulation of cell proliferation and tumorigenesis. Proc Natl Acad Sci USA 104:13331–13336CrossRefGoogle Scholar
- 26.Ferrara N (2000) Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 55:15–35; discussion 35–16Google Scholar
- 29.Potashnik G, Lunenfeld E, Shwartz I, Glezerman M, Roberts CT Jr, LeRoith D, Sharoni Y, Levy J (1995) Endogenous plasma growth hormone and the occurrence of pregnancies in patients undergoing in vitro fertilization and embryo transfer with ovarian stimulation. Hum Reprod 10:1065–1069CrossRefGoogle Scholar
- 40.Thum T, Hoeber S, Froese S, Klink I, Stichtenoth DO, Galuppo P, Jakob M, Tsikas D, Anker SD, Poole-Wilson PA, Borlak J, Ertl G, Bauersachs J (2007) Age-dependent impairment of endothelial progenitor cells is corrected by growth-hormone-mediated increase of insulin-like growth-factor-1. Circ Res 100:434–443CrossRefGoogle Scholar
- 44.Hartman ML, Xu R, Crowe BJ, Robison LL, Erfurth EM, Kleinberg DL, Zimmermann AG, Woodmansee WW, Cutler GB Jr, Chipman JJ, Melmed S, CCSAB International Hypo (2013) Prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs. untreated patients. J Clin Endocrinol Metab 98:980–988CrossRefGoogle Scholar